Spine BioPharma
Marc Viscogliosi, CEO

Over 266 million patients around the world are struggling with debilitating back pain, trying to avoid
invasive surgeries and the potential of opioid addiction. Spine BioPharma has developed a portfolio of
non-surgical solutions that will reduce pain, restore function and slow or stop pathological spinal disease
progression without using opioids. Spine BioPharma’s lead candidate, Remedisc™ is a first-in-class
disease-modifying therapeutic for the treatment of degenerative disc disease, offering clinical benefits of
pain relief, restoration of function and potential prevention of disease progression.